Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial.

Mukherjee S. et al, (2024), Eur J Cancer, 209

Development of human pancreatic cancer avatars as a model for dynamic immune landscape profiling and personalized therapy.

Hughes D. et al, (2024), Sci Adv, 10

53BP1-mediated recruitment of RASSF1A to ribosomal DNA breaks promotes local ATM signaling

Tsaridou S. et al, (2022), EMBO REPORTS

Chemical-induced gene expression ranking and its application to pancreatic cancer drug repurposing

Pham TH. et al, (2022), Patterns

RASSF1A disrupts the NOTCH signaling axis via SNURF/RNF4-mediated ubiquitination of HES1.

Papaspyropoulos A. et al, (2021), EMBO Rep

RASSF1C oncogene elicits amoeboid invasion, cancer stemness, and extracellular vesicle release via a SRC/Rho axis.

Tognoli ML. et al, (2021), EMBO J

TET2 drives 5hmc marking of GATA6 and epigenetically defines pancreatic ductal adenocarcinoma transcriptional subtypes.

Eyres M. et al, (2021), Gastroenterology

Ciliogenesis and Hedgehog signalling are supressed downstream of KRas during acinar-ductal metaplasia.

Bangs FK. et al, (2020), Dis Model Mech

Assessment of CCR5/maraviroc immunotherapy in combination with PD1 and MR-guided radiotherapy for treatment of pancreatic cancer.

Hughes S. et al, (2020), CANCER IMMUNOLOGY RESEARCH, 8, 120 - 120

Galectin-3 modulates postnatal subventricular zone gliogenesis.

Al-Dalahmah O. et al, (2020), Glia, 68, 435 - 450

Translational analysis from SCALOP trial: CCL5 as a prognostic biomarker and a potentially actionable target in locally advanced pancreatic cancer (LAPC)

Mukherjee S. et al, (2020), JOURNAL OF CLINICAL ONCOLOGY, 38

Assessment of CCR5i/maraviroc immunotherapy in combination with PD1 and MR-guided radiotherapy for treatment of pancreatic cancer

Lanfredini S. et al, (2019), CANCER RESEARCH, 79

Ciliogenesis and Hh signaling are suppressed downstream of KRas during ADM

Bangs F. and O'Neill E., (2019), CANCER RESEARCH, 79

High circulating CCL5 is associated with poor prognosis in locally advanced pancreatic cancer (LAPC): Biomarker analysis from the randomized phase II SCALOP trial

Willenbrock F. et al, (2019), CANCER RESEARCH, 79

Loss of TET2 activity results in epigenetic instability and drives PDAC molecular subtypes

Eyres M. et al, (2019), CANCER RESEARCH, 79

A screen for epigenetic reprogramming reveals LSD1 inhibitor as a potential intervention to promote differentiation in pancreatic cancer

Willenbrock F. et al, (2019), BRITISH JOURNAL OF CANCER, 121, 6 - 7

Cell culture under perfusion conditions reduces cellular metabolic stress and mimics the in vivo physiological environment in pancreatic cancer

Hughes D. et al, (2019), BRITISH JOURNAL OF CANCER, 121, 17 - 17

RASSF1A is required for the maintenance of nuclear actin levels.

Chatzifrangkeskou M. et al, (2019), EMBO J, 38

RAS in pancreatic cancer.

Lanfredini S. et al, (2019), Biochem Soc Trans

CCL5 is associated with poor prognosis in locally advanced pancreatic cancer (LAPC): biomarker analysis from the randomised phase II SCALOP trial

Willenbrock F. et al, (2019), ANNALS OF ONCOLOGY, 30, 110 - 110

Load More

1
2
3
4
5